Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Yahuafai, Jantana; Asai, Tomohiro; Oku, Naoto; Siripong, Pongpun

doi:10.1248/bpb.b17-00989

Cited by 15 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gundelia tournefortii , a member of the Asteraceae family, is famous for its valuable health benefits for diabetes, intestinal diseases, cancer, and epilepsy. Stigmasterol, an abundant phytosterol isolated from this plant, exhibits potential anticancer properties through the VEGF signaling pathway [121]. Stigmasterol inhibits angiogenesis through the VEGF signaling network.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy

Parveen

Subedi

Kim

et al. 2019

JCM

View full text Add to dashboard Cite

The role of vascular endothelial growth factor (VEGF) in cancer cells is not limited to angiogenesis; there are also multiple factors, such as neuropilins (non-tyrosine kinases receptors), tyrosine kinases receptors, immunodeficiencies, and integrins, that interact with VEGF signaling and cause cancer initiation. By combating these factors, tumor progression can be inhibited or limited. Natural products are sources of several bioactive phytochemicals that can interact with VEGF-promoting factors and inhibit them through various signaling pathways, thereby inhibiting cancer growth. This review provides a deeper understanding of the relation and interaction of VEGF with cancer-promoting factors and phytochemicals in order to develop multi-targeted cancer prevention and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Coptis chinensis belongs to the Ranunculaceae family and is used as a folk remedy to cure several diseases. Berberine, an active constituent of this plant, exerts its role in inhibiting cancer through an antiangiogenic mechanism; it inhibits VEGF expression in HUVECs with little toxicity [121].…”

Section: Resultsmentioning

confidence: 99%

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy

Parveen

Subedi

Kim

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…It is worth reiterating that poor intestinal absorption, extensive efflux by the action of P-gc and extensive degradation account to the rather poor bioavailability/pharmacokinetics profile of berberine. The various formulation approaches specifically designed to tackle this problem and improve berberine's anticancer efficacy are shown in Table 2 [106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123]. These include nanoparticles of various sizes and surface charges with some specifically targeting subcellular organelles, such as the mitochondria.…”

Section: Enhancement Of Berberine's Anticancer Effect Via Formulationmentioning

confidence: 99%

“…Yahuafai et al [114] Enhance antiproliferative activity in A549 (human lung adenocarcinoma) cells; no obvious severe hepatotoxicity, renal toxicity, and haemotoxicity in rats by i.v. Kim et al [115] Folic acid-and berberine-loaded silver nanomaterial (FA-PEG@BBR-AgNPs)…”

Section: Inhibit the Vascular Endothelial Growth Factor (Vegf) Expresmentioning

confidence: 99%

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Habtemariam

2020

Molecules

View full text Add to dashboard Cite

Berberine is multifunctional natural product with potential to treat diverse pathological conditions. Its broad-spectrum anticancer effect through direct effect on cancer cell growth and metastasis have been established both in vitro and in vivo. The cellular targets that account to the anticancer effect of berberine are incredibly large and range from kinases (protein kinase B (Akt), mitogen activated protein kinases (MAPKs), cell cycle checkpoint kinases, etc.) and transcription factors to genes and protein regulators of cell survival, motility and death. The direct effect of berberine in cancer cells is however relatively weak and occur at moderate concentration range (10–100 µM) in most cancer cells. The poor pharmacokinetics profile resulting from poor absorption, efflux by permeability-glycoprotein (P-gc) and extensive metabolism in intestinal and hepatic cells are other dimensions of berberine’s limitation as anticancer agent. This communication addresses the research efforts during the last two decades that were devoted to enhancing the anticancer potential of berberine. Strategies highlighted include using berberine in combination with other chemotherapeutic agents either to reduce toxic side effects or enhance their anticancer effects; the various novel formulation approaches which by order of magnitude improved the pharmacokinetics of berberine; and semisynthetic approaches that enhanced potency by up to 100-fold.

show abstract

“…Studies describing CSRA in soft tissue sarcoma patients are largely missing. ere are multiple studies describing cytotoxicity assays in sarcoma cell lines and anticancer activity in vivo, mainly in xenograft models [58][59][60][61]. More than 600 established sarcoma cell lines are available for screening, and, as STS is a highly heterogeneous group of cancer, there needs to be even a larger number of cell lines, with various histological subtypes, to better benefit sarcoma research [62].…”

Section: Drug Sensitivity Testing On Patient-derived Sts Cellsmentioning

confidence: 99%

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Кирсанов

Lesovaya

Fetisov

et al. 2020

Sarcoma

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.

show abstract

Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice

Abstract: Berberine, the main isoquinoline alkaloid obtained from traditional plants, e.g., Berberis, Coptis, Coscinium spps., etc., is known to exhibit anticancer activity in vitro and in vivo.

Cited by 15 publications

References 12 publications

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy

Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Contact Info

Product

Resources

About